Jacobs Engineering

Merck is constructing a $69 million facility for the production of high-potency active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) compounds. Representing an expansion of the company's existing campus near Madison, the 70,000-sf structure will feature containment environments specifically designed for the manufacture of substances with single-digit nanogram occupational exposure limits. The building will allow the large-scale production of increasingly potent compounds for the creation of innovative cancer therapeutics.